NCT01468207.

Trial name or title	A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa ‐ PIONEER I
Methods	This is a phase 3 parallel RCT
Participants	The trial is including adults with moderate to severe HS
Interventions	Adalimumab every week/adalimumab alternate weeks/placebo
Outcomes	Clinical response at week 12
Starting date	November 2011
Contact information	David Williams MD Study Chair, Abbott Andrea L Byars (andrea.byars@abbott.com)
Notes	AbbVie sponsor the trial (prior sponsor: Abbott). Results are currently available in 2 conference abstracts, which have not yet been published in full in a peer‐reviewed journal